Ivím Health
US$ 28.32
glp-1 receptor agonists in idiopathic intracranial hypertension Novel use of agonist therapy for pediatric hypertension: a case report The effect of glucagon-like peptide-1
Description
10.7326/ANNALS-25-00716
Among the 4 brand-name products with paragraph IV submissions, the median time from brand-name approval to first paragraph IV challenge was 6.8 years (IQR: 6.0-7.4)
(ePub ahead of print)
During the same period, expenses on T2D GLP-1s soared from 0.2 percent to 5.8 percent of Medicare Part D spending
